Compositions and methods for treating granulomatosis with polyangiitis
AssigneeCanem Holdings, LLC
InventorAdam Haeberle
Life of this patent
Estimating the term…
Abstract
The present specification disclose methods and uses for the treatment of a vasculitic syndrome. The disclosed methods comprise administering a composition comprising a Proteinase 3 (PR3) inhibitor to a patient in need thereof. Also disclosed are compositions comprising a PR3 inhibitor disclosed herein for use in the treatment of a vasculitic syndrome as well as use of a composition comprising a PR3 inhibitor disclosed herein in the treatment of a vasculitic syndrome. The present specification also discloses use of a composition comprising a PR3 inhibitor disclosed herein in the manufacture of a medicament for the treatment of a vasculitic syndrome.
Claims9
A method for treating Granulomatosis with Polyangiitis (GPA) consisting essentially of the step of administering a therapeutically effective amount of a Proteinase 3 (PR3) inhibitor to a patient not having a A1PI deficient genotype in need thereof, wherein administration inhibits the physiological function of PR3 thereby treating GPA, wherein PR3 inhibitor is α-1 Protease Inhibitor (A1PI).
Dependencies are inferred from the claim text.